230 related articles for article (PubMed ID: 29624862)
1. The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
Furlan T; Khalid S; Nguyen AV; Günther J; Troppmair J
Mol Oncol; 2018 Jun; 12(6):869-882. PubMed ID: 29624862
[TBL] [Abstract][Full Text] [Related]
2. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
3. cJun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66Shc activation.
Khalid S; Drasche A; Thurner M; Hermann M; Ashraf MI; Fresser F; Baier G; Kremser L; Lindner H; Troppmair J
Sci Rep; 2016 Feb; 6():20930. PubMed ID: 26868434
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
Chen B; Tardell C; Higgins B; Packman K; Boylan JF; Niu H
PLoS One; 2012; 7(8):e42598. PubMed ID: 22880048
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
7. Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis.
Liang L; Zhang Z
Cell Physiol Biochem; 2016; 38(4):1618-30. PubMed ID: 27119348
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.
Parker R; Clifton-Bligh R; Molloy MP
Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855
[TBL] [Abstract][Full Text] [Related]
9. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
11. The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.
Cardoso C; Serafim RB; Kawakami A; Gonçalves Pereira C; Roszik J; Valente V; Vazquez VL; Fisher DE; Espreafico EM
Pigment Cell Melanoma Res; 2019 Mar; 32(2):303-314. PubMed ID: 30457212
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
13. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
14. The mitochondrial reactive oxygen species regulator p66Shc controls PDGF-induced signaling and migration through protein tyrosine phosphatase oxidation.
Frijhoff J; Dagnell M; Augsten M; Beltrami E; Giorgio M; Östman A
Free Radic Biol Med; 2014 Mar; 68():268-77. PubMed ID: 24378437
[TBL] [Abstract][Full Text] [Related]
15. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
16. MAP kinase signaling and inhibition in melanoma.
Sullivan RJ; Flaherty K
Oncogene; 2013 May; 32(19):2373-9. PubMed ID: 22945644
[TBL] [Abstract][Full Text] [Related]
17. P66Shc, a key regulator of metabolism and mitochondrial ROS production, is dysregulated by mouse embryo culture.
Edwards NA; Watson AJ; Betts DH
Mol Hum Reprod; 2016 Sep; 22(9):634-47. PubMed ID: 27385725
[TBL] [Abstract][Full Text] [Related]
18. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.
Niessner H; Burkard M; Leischner C; Renner O; Plöger S; Meraz-Torres F; Böcker M; Hirn C; Lauer UM; Venturelli S; Busch C; Sinnberg T
Cells; 2022 Apr; 11(7):. PubMed ID: 35406796
[TBL] [Abstract][Full Text] [Related]
20. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
